We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Multicenter, Multi-national Open-label Program to Provide BMN 190 to Patients Diagnosed With CLN2 Disease

This treatment has been approved for sale to the public.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02963350
First Posted: November 15, 2016
Last Update Posted: July 24, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
BioMarin Pharmaceutical
November 9, 2016
November 15, 2016
July 24, 2017
 
A Multicenter, Multi-national Open-label Program to Provide BMN 190 to Patients Diagnosed With CLN2 Disease
  • To provide access to BMN 190 to patients with CLN2 disease who cannot participate in a clinical trial.
  • To collect additional information on the safety and tolerability of BMN 190 administration in patients with CLN2 disease.
Not Provided
Expanded Access
Drug: BMN190, recombinant human tripeptidyl peptidase-1 (rhTPP1)
Not Provided
 
Approved for marketing
Contact information is only displayed when the study is recruiting subjects
Germany,   Italy,   United Kingdom,   United States
 
 
NCT02963350
BioMarin Pharmaceutical
BioMarin Pharmaceutical
Not Provided
Study Director: Jessica Cohen Pfeffer, MD Medical Monitor
BioMarin Pharmaceutical
July 2017